Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral
administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral
administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.